Franklin Biotechnology Discv A(acc)HKD |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | 17.0 | -11.1 | -6.8 | 13.3 | 7.6 | |
+/-Cat | -2.3 | -8.0 | 6.0 | 12.2 | 10.0 | |
+/-Idx | -8.9 | -18.0 | -3.7 | 3.4 | -0.4 | |
Category: Sector Equity Biotechnology | ||||||
Benchmarks: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 16/05/2024 | HKD 26.76 | |
Day Change | -0.34% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU0889565916 | |
Fund Size (Mil) 30/04/2024 | USD 1625.86 | |
Share Class Size (Mil) 16/05/2024 | HKD 65.68 | |
Max Initial Charge | 5.75% | |
Ongoing Charge 04/03/2024 | 1.82% |
Morningstar Research |
Analyst Report | 13/10/2023 Katie Rushkewicz Reichart, Director Morningstar, Inc |
Franklin Biotechnology Discovery is overseen by experienced managers, but limited resources and an undifferentiated process earn the fund a Morningstar Analyst Rating of Neutral.This strategy’s compact team is composed of three managers who have... | |
Click here to read this analyst report |
Morningstar Pillars | |
---|---|
People | 23 |
Parent | 23 |
Process | 23 |
Performance | |
Price |
Investment Objective: Franklin Biotechnology Discv A(acc)HKD |
The Fund’s investment objective is capital appreciation. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Wendy Lam 01/09/2018 | ||
Click here to see others | ||
Inception Date 26/02/2013 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Franklin Biotechnology Discv A(acc)HKD | 30/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 7.08 |
Regeneron Pharmaceuticals Inc | Healthcare | 6.34 |
Vertex Pharmaceuticals Inc | Healthcare | 5.39 |
Ascendis Pharma A/S ADR | Healthcare | 4.07 |
AstraZeneca PLC ADR | Healthcare | 3.69 |
Increase Decrease New since last portfolio | ||
Franklin Biotechnology Discv A(acc)HKD |